Literature DB >> 22531022

The challenging management of a child with type 3 von Willebrand disease and antibodies to von Willebrand factor.

H Pergantou, P Xafaki, E Adamtziki, P Koletsi, A Komitopoulou, H Platokouki.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22531022     DOI： 10.1111/j.1365-2516.2012.02799.x

Source DB:  PubMed          Journal:  Haemophilia        ISSN： 1351-8216            Impact factor:   4.287


× No keyword cloud information.
  7 in total

1.  Skin testing, graded challenge, and desensitization to von Willebrand factor (VWF) products in type III von Willebrand disease (VWD).

Authors:  Craig D Platt; Loren D'Angelo; Ellis J Neufeld; Ana Dioun Broyles
Journal:  J Allergy Clin Immunol Pract       Date:  2016-07-09

Review 2.  Alloantibodies in von Willebrand disease.

Authors:  Paula D James; David Lillicrap; Pier M Mannucci
Journal:  Blood       Date:  2013-01-07       Impact factor: 22.113

Review 3.  Von Willebrand Disease: Current Status of Diagnosis and Management.

Authors:  Angela C Weyand; Veronica H Flood
Journal:  Hematol Oncol Clin North Am       Date:  2021-08-13       Impact factor: 3.722

4.  Successful Desensitization of a Patient with Possible IgE-Mediated Anaphylactic Reaction to FVIII/VWF Concentrate.

Authors:  Burcin Beken; Velat Celik; Pinar Gokmirza Ozdemir; Tuba Eren; Mehtap Yazicioglu
Journal:  Pediatr Allergy Immunol Pulmonol       Date:  2019-06-17       Impact factor: 1.349

Review 5.  The diagnosis and management of von Willebrand disease: a United Kingdom Haemophilia Centre Doctors Organization guideline approved by the British Committee for Standards in Haematology.

Authors:  Mike A Laffan; Will Lester; James S O'Donnell; Andrew Will; Robert Campbell Tait; Anne Goodeve; Carolyn M Millar; David M Keeling
Journal:  Br J Haematol       Date:  2014-08-12       Impact factor: 6.998

6.  Monitoring of von Willebrand factor inhibitors in patients with type 3 von Willebrand disease using a quantitative assay.

Authors:  Connie H Miller
Journal:  Haemophilia       Date:  2021-06-05       Impact factor: 4.263

7.  Efficacy of Octocog Alfa (Advate) in a Child with Type 3 von Willebrand Disease and Alloantibodies.

Authors:  Gianluca Sottilotta; Francesca Luise; Elisabetta Massara; Vincenzo Oriana; Angela Piromalli
Journal:  J Clin Med       Date:  2017-09-18       Impact factor: 4.241
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.